Innovent Biologics, Inc. logo

Innovent Biologics, Inc.

Innovent Biologics is a biopharma and contract manufacturing company, developing monoclonal antibodies for the treatment of cancer and autoimmune diseases.

Innovent Biologics biopharmaceutical facility is one of the largest biologics production facility in China designed to comply with international quality requirements.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”1801.HK” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://innoventbio.com
Founded2011
Disease Focus
Development Stage
STOCK CODEHKG: 1801
Address
168 Dongping Street, Suzhou Industrial Park, 215123
Suzhou
China
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/innovent-biologics-inc-” connections=”true” suffix=””]

Pipeline

IBI301 is a monoclonal antibody against CD20, which is primarily found on the surface of B-cells.

IBI302 is a bispecific monoclonal antibody, which blocks two critical genes in disease pathway of cancers.

As per new the agreement, Innovents all three cancer programs are in collaboration with Eli Lilly.

In Oct 2015, Lilly extend its liscence agreement with Innovent to further collaborate to support the development and potential commercialization of up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, both inside and outside of China. Under the terms of the expanded agreement, Innovent could receive additional milestones totaling more than $1 billion if the products reach certain development, regulatory and sales milestones, both inside and outside of China.

In Mar 2015, Eli Lilly and Innovent Biologics signs an agreement to creates possible new treatment options for cancer patients.
Innovent received $56 Mn as an upfront payment and upto $400 Mn as future payments for the pre-clinical immuno-oncology molecule if the product reaches certain development, regulatory and sales milestones.

In June 2016, EpimAb signed agreement with Innovent for the development of bispecific antibodies. As per the terms, Innovent gains access to EpimAbs proprietary Fabs-In-Tandem Immunoglobulin platform to develop multiple bispecific antibodies for the Chinese market. In return, EpimAb receives an upfront payment and total milestones of up to USD 120 Mn, plus royalties.

In June 2016, Innovent Biologics and Adimab LLC signed over three years research collaboration under, which Adimab will use its proprietary yeast-based discovery platform to generate IgGs or bispecifics for development as therapeutic products for multiple targets chosen by Innovent and Innovent will retain worldwide commercial rights to these therapeutic products. The financial terms were not disclosed.

In Apr 2018, Innovent raised $150 Mn in Series E financing led by Capital Group Private Markets (CGPM). New investors including Cormorant Asset Management, Rock Springs Capital and Ally Bridge Group as well as the existing investors Temasek, Hillhouse, Legend Capital, Lilly Asia Venture and Taikang Insurance participated in this round.

In Nov 2016, Innovent raised $260 Mn in Series D financing led by Future Industry Investment Fund (FIIF), along with other blue chip investors including China Life Private Equity Limited, Milestone, Ping An and Taikang Insurance Group. Innovents existing international investors, specifically Legend Capital, Temasek and Hillhouse Capital, also participated in this financing.

In Jan. 2015, Innovent raised $100 Mn in Series C financing. Key investors in the company includes Legend Capital, Temasek, Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures and Frontline Bioventures.